The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Asthma Endotypes and an Overview of Targeted Therapy for Asthma
Open accessAbstract
Guidelines for the management of severe asthma do not emphasize the measurement of the inflammatory component of airway disease to indicate appropriate treatments or to monitor response to treatment. Inflammation is a central component of asthma and contributes to symptoms, physiological, and structural abnormalities. It can be assessed by a number of endotyping strategies based on "omics" technology such as proteomics, transcriptomics, and metabolomics. It can also be assessed using simple cellular responses by quantitative cytometry in sputum. Bronchitis may be eosinophilic, neutrophilic, mixed-granulocytic, or paucigranulocytic (eosinophils and neutrophils not elevated). Eosinophilic bronchitis is usually a Type 2 (T2)-driven process and therefore a sputum eosinophilia of greater than 3% usually indicates a response to treatment with corticosteroids or novel therapies directed against T2 cytokines such as IL-4, IL-5, and IL-13. Neutrophilic bronchitis represents a non-T2-driven disease, which is generally a predictor of response to antibiotics and may be a predictor to therapies targeted at pathways that lead to neutrophil recruitment such as TNF, IL-1, IL-6, IL-8, IL-23, and IL-17. Paucigranulocytic disease may not warrant anti-inflammatory therapy. These patients, whose symptoms may be driven largely by airway hyper-responsiveness may benefit from smooth muscle-directed therapies such as bronchial thermoplasty or mast-cell directed therapies. This review will briefly summarize the current knowledge regarding "omics-based signatures" and cellular endotyping of severe asthma and give an overview of segmentation of asthma therapeutics guided by the endotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Cited by
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
Flume, P. A., Chalmers, J. D., & Olivier, K. N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31767-7 · Cited by 545
Phenotypes and endotypes of adult asthma: Moving toward precision medicine
Kaur, R., & Chupp, G. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.05.031 · Cited by 457
Hough, K. P., Curtiss, M. L., Blain, T. J., Liu, R.-M., Trevor, J., Deshane, J. S., & Thannickal, V. J. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00191 · Cited by 432
Epithelial cell dysfunction, a major driver of asthma development
Heijink, I. H., Kuchibhotla, V. N. S., Roffel, M. P., Maes, T., Knight, D. A., Sayers, I., & Nawijn, M. C. (2020) · Allergy · doi:10.1111/all.14421 · Cited by 326
Eosinophils from Physiology to Disease: A Comprehensive Review
Ramirez, G. A., Yacoub, M.-R., Ripa, M., Mannina, D., Cariddi, A., Saporiti, N., Ciceri, F., Castagna, A., Colombo, G., & Dagna, L. (2018) · BioMed Research International · doi:10.1155/2018/9095275 · Cited by 316
Metadata
- Authors
- Svenningsen, S., & Nair, P.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2017-09-26
- Volume
- 4
- Pages
- 158-158
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2760056674
- Cited by
- 252
- References
- 1
- FWCI
- 16.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Asthma Endotypes and an Overview of Targeted Therapy for Asthma. https://app.cochat.ai/papers/10.3389/fmed.2017.00158
- The paper
- Svenningsen, S., & Nair, P. (2017). Asthma Endotypes and an Overview of Targeted Therapy for Asthma. Frontiers in Medicine. https://doi.org/10.3389/fmed.2017.00158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.